KAHR Medical Israeli Company
KAHR is developing immuno-oncology drug candidates for the treatment of multiple types of cancer. Its lead product, DSP107, is a CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses, and activates an effective local response of both innate and adaptive immunity.
Health Tech & Life Sciences
Biotechnology
Medical
Pharmaceutical
Alternatives
No alternatives listed yet.
Suggest an Alternative
Parent Companies/Investors
Office Locations
Modi'in-Maccabim-Re'ut, Israel
References
[1]
finder.startupnationcentral.org
- https://finder.startupnationcentral.org/company_page/kahr-medical
[2]
crunchbase.com
- https://www.crunchbase.com/organization/kahr-medical
External links are provided for reference and verification purposes.